See more : Singapore Exchange Limited (SPXCY) Income Statement Analysis – Financial Results
Complete financial analysis of Bolt Biotherapeutics, Inc. (BOLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bolt Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Croda International Plc (CRDA.L) Income Statement Analysis – Financial Results
- Aventura Group AB (publ) (AVENT-B.ST) Income Statement Analysis – Financial Results
- Wearable Health Solutions, Inc. (WHSI) Income Statement Analysis – Financial Results
- Harworth Group plc (HWG.L) Income Statement Analysis – Financial Results
- Kokopelli Inc. (4167.T) Income Statement Analysis – Financial Results
Bolt Biotherapeutics, Inc. (BOLT)
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.88M | 5.73M | 1.26M | 231.00K | 215.00K | 0.00 |
| Cost of Revenue | 1.88M | 4.89M | 3.67M | 40.36M | 26.00M | 302.00K |
| Gross Profit | 5.99M | 838.00K | -2.41M | -40.13M | -25.79M | -302.00K |
| Gross Profit Ratio | 76.08% | 14.63% | -191.43% | -17,370.56% | -11,993.95% | 0.00% |
| Research & Development | 61.54M | 73.12M | 75.66M | 40.36M | 26.00M | 9.42M |
| General & Administrative | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Other Expenses | 0.00 | 0.00 | -6.08M | -11.75M | -42.00K | -153.00K |
| Operating Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Cost & Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Interest Income | 7.00M | 2.22M | 281.00K | 199.00K | 524.00K | 193.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.85M | 4.89M | 3.67M | 2.50M | 1.33M | 302.00K |
| EBITDA | -74.34M | -88.66M | -91.60M | -48.57M | -30.63M | -11.33M |
| EBITDA Ratio | -943.91% | -1,547.48% | -6,786.59% | -15,941.99% | -14,228.84% | 0.00% |
| Operating Income | -76.20M | -90.32M | -92.79M | -49.18M | -30.97M | -11.63M |
| Operating Income Ratio | -967.45% | -1,576.56% | -7,364.13% | -21,290.91% | -14,404.19% | 0.00% |
| Total Other Income/Expenses | 7.00M | 2.22M | -5.80M | -11.55M | 482.00K | 40.00K |
| Income Before Tax | -69.20M | -88.10M | -98.59M | -60.73M | -30.49M | -11.59M |
| Income Before Tax Ratio | -878.58% | -1,537.76% | -7,824.68% | -26,289.18% | -14,180.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.22M | 5.80M | 11.55M | -482.00K | 40.00K |
| Net Income | -69.20M | -85.88M | -104.39M | -72.27M | -30.01M | -11.59M |
| Net Income Ratio | -878.58% | -1,498.95% | -8,285.24% | -31,287.45% | -13,955.81% | 0.00% |
| EPS | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| EPS Diluted | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| Weighted Avg Shares Out | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
| Weighted Avg Shares Out (Dil) | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
CSE Bulletin: Stock Split - Bolt Metals Corp. (BOLT)
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
Bolt Biotherapeutics Announces Changes to its Board of Directors
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit
BOLT FINAL DEADLINE: Bronstein, Gewirtz and Grossman, LLC Reminds Bolt Biotherapeutics, Inc. Shareholders of Final Hours to Lead Class Action!
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Source: https://incomestatements.info
Category: Stock Reports